What is Theravance Biopharma Operating Cash Flow per Share?
Theravance Biopharma's operating cash flow per share for the
three
months ended in Dec. 2023 was $-0.02.
Theravance Biopharma's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.46.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 50.50% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 23.00% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 11.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Theravance Biopharma's Operating Cash Flow per Share or its related term are showing as below:
TBPH'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -24.6 Med: 11.4 Max: 50.5
Current: 50.5
During the past 12 years, Theravance Biopharma's highest 3-Year average Operating Cash Flow per Share Growth Rate was 50.50% per year. The lowest was -24.60% per year. And the median was 11.40% per year.
TBPH's 3-Year OCF Growth Rate is ranked better than 91.14% of 1241
companies
in the Biotechnology industry
Industry Median: 3.8
vs TBPH: 50.50
Theravance Biopharma Operating Cash Flow per Share Historical Data
The historical data trend for Theravance Biopharma's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Theravance Biopharma Operating Cash Flow per Share Chart
Competitive Comparison of Theravance Biopharma's Operating Cash Flow per Share
For the Biotechnology subindustry, Theravance Biopharma's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theravance Biopharma's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Theravance Biopharma's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Theravance Biopharma's Price-to-Operating-Cash-Flow falls into.
Theravance Biopharma Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Theravance Biopharma's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.46
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theravance Biopharma Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Theravance Biopharma's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Theravance Biopharma (Theravance Biopharma) Business Description
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TBPH has been successfully added to your 